期刊
EXPERT REVIEW OF VACCINES
卷 11, 期 6, 页码 645-657出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/ERV.12.42
关键词
bivalent vaccine; Cervarix (R); cervical cancer; HPV vaccine; human papillomavirus
类别
资金
- GlaxoSmithKline
- Merck
Cervical cancer is the third most common cancer in women worldwide and often affects women under 40 years of age with young families. Vaccination against HPV is a major advancement, as it offers primary prevention against the infectious agent that is the main cause of the disease. The bivalent AS04-adjuvanted prophylactic HPV vaccine provides high efficacy against disease associated with HPV 16 and 18, as well as significant cross-protection against some HPV types not included in the vaccine. Protection against HPV 45 may be particularly important, as it is relatively more common in adenocarcinoma. The vaccine's antibody response profile suggests a long duration of immunity. Safety data have been reassuring, which is not unexpected, given that the vaccine is composed of virus-like particles, rather than being a live-virus vaccine.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据